FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved Eucrisa ...

Please provide your email address to receive an email when new articles are posted on . Median time of flare-free maintenance was 111 days in the crisaborole group vs. 30 days in vehicle group. Those ...

The outlook for the PDE4B inhibitors market is changing as this drug class demonstrates significant therapeutic promise in respiratory, dermatologic, and inflammatory diseases. Existing approvals such ...

Atopic dermatitis is one of the most common chronic inflammatory skin diseases worldwide and is also the most common form of eczema. Although infants and children are most often affected, adults can ...

Biologics are some of the newest treatment options for atopic dermatitis. Biologics have been around for years as treatment options for many conditions that affect the immune system, but the FDA ...

Pune, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The global dermatitis drugs market size will expand considerably in the coming years driven by the advancements across numerous drug classes. According to a ...